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Aims The purpose of the present study was to investigate the relationship between in-stent neoatherosclerosis (NA) and
native atherosclerosis progression of untreated coronary segments.
Methods
and results
In-stent NAwas assessed by optical coherence tomography (OCT) among patients included in the SIRTAX-LATEOCT
study 5 years after drug-eluting stent (DES) (sirolimus-eluting and paclitaxel-eluting stents) implantation. Neoathero-
sclerosis was defined as the presence of fibroatheroma or fibrocalcific plaque within the neointima of stented seg-
ments with a longitudinal extension .1.0 mm. Atherosclerosis progression in untreated native coronary segments
was evaluated by serial quantitative coronary angiography (QCA). The change in minimal lumen diameter (MLD)
was serially assessed within matched segments at baseline and 5-year angiographic follow-up. The key clinical endpoint
was non-target lesion (non-TL) revascularization throughout 5 years. A total of 88 patients with 88 lesions were avail-
able for OCT analysis 5 years after DES implantation. In-stent NA was observed in 16% of lesions with the majority of
plaques being fibroatheromas (11.4%) followed by fibrocalcific plaques (5.7%). A total of 704 non-TL segments were
serially evaluated by QCA. Between baseline and 5-year follow-up, the reduction in MLD was significantly more
pronounced in patients with NA (20.25 mm, 95% CI 20.36 to 20.17 mm) when compared with patients without
NA (20.13 mm, 95% CI 20.17 to 20.10 mm, P ¼ 0.002). Similarly, non-TL revascularization was more frequent in
patients with NA (78.6%) when compared with patients without NA (44.6%, P ¼ 0.028) throughout 5 years.
Conclusions In-stent NA is more common among patients with angiographic and clinical evidence of native atherosclerosis progres-
sion suggesting similar pathophysiological mechanisms.
SIRTAX trial is registered at http://www.clinicaltrials.gov/ct2/show/NCT00617084.
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Clinical perspective
The significant association between in-stent neoatherosclerosis (NA) and progression of native coronary atherosclerosis suggests similar
pathophysiological mechanisms. Therapeutic strategies known to attenuate atherosclerosis progression—such as high-dose statin
therapy—may be also effective to suppress the development or progression of NA. In addition, the impact of NA on cardiovascular events
has not been sufficiently investigated and requires confirmation in adequately powered observational intra-coronary imaging studies.
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Introduction
Drug-eluting stents (DES) reduce the risk of repeat revasculariza-
tion compared with bare metal stents, but late stent failure may still
occur due to restenosis or stent thrombosis. In-stent neoathero-
sclerosis (NA)—a novel disease entity—is characterized by the de-
velopment of atherosclerotic changes in the nascent neointimal
tissue within previously implanted stents. Although there is no
large–scale prospective study assessing the impact of NA on late
stent failure and associated clinical outcomes, NA has been identi-
fied as the culprit for delayed in-stent-restenosis or stent throm-
bosis in intra-coronary imaging studies and case reports.1 – 3
Accordingly, NAmay represent an accelerated and possibly more un-
stable manifestation of atherosclerosis.1,4 While histological analyses
were performed for the documentation of NA in human ex vivo path-
ology studies, optical coherence tomography (OCT) is able to accur-
ately characterize the in vivo vascular response after stent implantation
including the development of in-stent NA.1,3
Despite the potential clinical impact of NA during the long-term
course following DES implantation, little is known about the patho-
physiological mechanisms underlying the development of NA. Based
on histological similarities between NA and native atherosclerosis,
we hypothesized that patients with progression of atherosclerosis
in native coronary segments would be at increased risk for the de-
velopment of NA within stented segments.4 We therefore investi-
gated the type and frequency of in-stent NA as assessed by OCT
and native atherosclerosis progression in the entire untreated cor-
onary artery tree assessed by quantitative coronary angiography
(QCA) among patients included in the SIRTAX-LATE OCT cohort
study 5 years after DES implantation.5
Methods
Patient population
The design and results of the SIRTAX and SIRTAX-LATE study
(Sirolimus-Eluting Stent Compared With Paclitaxel-Eluting Stent for
Coronary Revascularisation) have been previously reported.6,7 For
the purpose of the present study, we analysed all patients included
in the SIRTAX-LATE OCT study. Among 145 patients who under-
went angiographic follow-up 5 years after DES implantation between
December 2008 and July 2009, 88 patients with 88 lesions were in-
cluded in the OCT study.5 A detailed patient flow is shown in Figure 1.
The study complied with the Declaration of Helsinki regarding investi-
gation in humans and was approved by the institutional ethics commit-
tees at Bern University Hospital, Switzerland. All patients provided
written informed consent.
Optical coherence tomography imaging and
analysis
Optical coherence tomography was performed with a time domain M2
system (Lightlab Imaging, Westford, MA, USA) using a pullback speed of
2 mm/s and the non-occlusive flushing technique. After the diagnostic
angiography and administration of 5000 IU unfractionated heparin, the
ImageWire (Lightlab Imaging) was carefully advanced distal to the study
lesion. Following administration of 200 mg of intra-coronary nitrogly-
cerin, the target vessel was flushed via the guiding catheter with nonio-
nic, isomolar contrast liquid using a power injector with flush rates
between 3 and 5 mL/s. Optical coherence tomography pullbacks were
assessed offline using a proprietary software (Lightlab Imaging). Stented
segments were analysed for strut coverage, apposition, and protrusion
at frames with 1-mm interval by two independent analysts blinded
(L.R. and S.B.) for stent type. For in-stent NA assessment, frames
were analysed at 0.125 mm intervals by two independent investigators
(L.R. and M.T.). Frames were considered not analysable whenmore than
one-quarter of the circumference was not visible due to insufficient
flush or out of zoom. Definitions used for stent strut analyses were
previously reported.5
Neointima was defined as the tissue between the luminal border
and the endoluminal border of the struts. Neoatherosclerosis lesion
was defined as the presence of a fibroatheroma or fibrocalcific plaques
within the neointima of a stented segment with a longitudinal extension
of ≥1 mm. A gap of at least 0.5 mm was used to define the boundary
between two NA lesions.
Fibroatheroma (FA)were characterized as a signal-poor region display-
ing a high attenuation (to differentiate from layered neointima) with
diffuse borders and a lateral extension of at least one quadrant.8 Thin-cap
fibroatheroma (TCFA) were defined as FA with a fibrous cap ≤65 mm
and thick-cap fibroatheroma (ThCFA) with a fibrous cap .65 mm.
Fibrocalcific plaques were defined as signal-poor region with low attenu-
ation and clear borderlines extending over one quadrant. Whenever the
calcific pool was located both inside and behind the stent, we disregarded
the presence of NA. Signal rich bands, suggestive of macrophage accumu-
lations, were defined as lines or dots with strong signal attenuation
producing a shadow with a sharply delineated lateral border.
Additional characteristics which potentially reflect neoatherosclero-
tic changes were investigated and their definition are provided in
Supplementary material online, Data. To determine the intra- and inter-
observer reproducibility of NA assessment, 20 OCT pullbacks were
randomly chosen and analysed by two assessors at two time points
(2 months apart) and then Cohen’s Kappa was calculated.
Quantitative coronary angiography analysis
After administration of intra-coronary nitroglycerin, standard biplane
angiographic images were obtained so that each coronary segment
was recorded in at least two orthogonal views. All angiographies
were analysed by the angiographic core laboratory at Bern University
Hospital. Assessors were blinded to the OCT analysis and clinical out-
comes. Methods for the serial assessment of the target lesions (TLs)
were previously reported.7 All three major untreated epicardial vessels
including all side branches with a reference vessel diameter (RVD) of
.1.5 mm in diameter were assessed byQCA at baseline and at follow-up
using similar projections whenever possible. For this purpose, segments
were divided in subsegments according to the modified American Heart
Association/American College of Cardiology (AHA/ACC) classification
using the QCA—CMS software version 7.3 (Medis Medical Imaging
Systems, Leiden, the Netherlands) (Figure 2).9,10 Minimal lumen diameter
(MLD), RVD, segment length, and diameter stenosis ([1 – MLD/RVD] ×
100) were assessed. In case a segment was revascularized prior to the
5-year follow-up examination, the latest available angiography prior to
revascularization was used for analysis. The change of all variables was
derived for each segment as outcome (follow-up) – outcome (baseline).
The angiographic endpoint was mean change in MLD.
Clinical follow-up
An independent clinical events committee adjudicated all data on case
report forms. All adverse events were assessed in hospital, at 1, 6,
and 9 months, and on an annual basis up to 5 years. The clinical endpoint
of this study was the occurrence of any non-TL revascularization within
the 5-year angiographic follow-up window. Non-TL revascularization
was defined as any revascularization except for TLR. Definitions of sec-
ondary clinical endpoints are provided in the Supplementary material
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online, Data. To further investigate the clinical impact of NA findings, we
extended the clinical follow-up to 9 years from index procedure (until
July 2013).
Statistical analysis
Comparison of baseline characteristics, medication, lipid profiles, and
stents were performed withWilcoxon rank-sum or Fisher’s exact tests.
Stratification: Patients were stratified in two groups according to the
presence of at least one NA plaque detected by OCT at 5-year follow-
up in the TL (based on criterion that an NA plaque is ≥1.0 mm).
Optical coherence tomography: Frame-level OCT outcomes were
analysed with linear mixed models with patient as random intercept
and lesion-level OCT outcomes with linear models.
Quantitative coronary angiography: Quantitative coronary angiog-
raphy outcomes were recorded for several segments per patient at base-
line and at angiographic follow-up. The absolute change from baseline to
follow-up was computed for each segment. Patient-level outcomes and
their changes were then derived by taking the arithmetic mean over sev-
eral segments. To compare the strata, medians taken over the patients
are reported with 95% CIs from non-parametric bootstrap with P-values
from Wilcoxon rank-sum tests.
Clinical events: The occurrence of revascularization events up to and
including the 5-year angiographic follow-up was compared between the
strata. Analyses were based on the first event per patient. Crude per-
centages are reported, odds ratios and P-values are from logistic regres-
sion models. Statistical analyses were done with the computing
environment R (The R Foundation for Statistical Computing) and with
Stata (StataCorp, College Station, TX, USA).
Results
Frequency, type, and distribution of
neoatherosclerosis
A total of 97% (11 772/12 124 frames) of all OCT frames were suit-
able for analysis. Neoatherosclerosis formation was observed in 14
(15.9%) of 88 lesions with the majority of plaques fulfilling the diag-
nostic criteria of fibroatheromas (N ¼ 9, 10.2%) and less frequently
fibrocalcific plaques (N ¼ 4, 4.5%) and both plaque types in one
case (N ¼ 1, 1.2%) (Table 1, Figure 3). Multiple NA lesions in the
same stent were observed in four lesions (4.5%). The intra- and
inter-observer reproducibility (Cohen’s Kappa) were 0.886 and
0.857, respectively. The most frequently observed findings poten-
tially related to NA were signal rich bands, which were observed
in 31.8% of stents. Other findings potentially related to NA were
infrequent (microvessels: 2.3%, surface erosion: 3.4%).
Neoatherosclerosis was more common among lesions treated
with PES (25.5%) compared with sirolimus-eluting stent (SES;
4.9%; P ¼ 0.009) and differences between stent types applied
to both the frequency of fibrocalcific plaques (SES 0 vs. PES
10.6%, P ¼ 0.058) as well as fibroatheromas (SES 4.9 vs. PES
17.0%, P ¼ 0.10). Similarly, signal rich bands were more frequent
among lesions treated with PES than SES (46.8 vs. 14.6%, P ¼ 0.001).
Baseline characteristics of patients with
and without neoatherosclerosis
Baseline clinical, angiographic, and procedural characteristics of
patients with and without NA are summarized in Table 2.
No significant differences were recorded with the exception of
type of implanted stent as mentioned above. We assessed the ad-
herence to cardiovascular medications including acetylsalicylic
acid, b-blocker, angiotensin converting enzyme (ACE) inhibitor/
angiotensin receptor (AR) blocker, statin, or their combination
throughout 5 years. There was no difference in the intake of any
of these medications (or combinations of 1, 2, or 3 medications) be-
tween patients with compared with those without NA throughout
5 years (Supplementary material online, Table S1). In addition, no dif-
ference in lipid levels at baseline or at 5 years was noted and no dif-
ference in the reduction of low-density lipoprotein-cholesterol
Figure 1 Study flow.
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(LDL-C) over 5 years (NA: 225.9 vs. no-NA: 29.1 mg/dL, P¼ 0.62)
or change in high-density lipoprotein-cholesterol (HDL-C) over
5 years (NA 21.4 vs. no-NA 22.6 mg/dL, P ¼ 0.85) was observed.
Optical coherence tomography analysis
Optical coherence tomography findings at 5 years in lesions
with and without NA are summarized in Supplementary material
online, Table S2. Lesions with NA showed a thicker neointima
(0.15 vs. 0.11 mm, P ¼ 0.001), neointimal area (1.27 vs. 0.96 mm2,
P ¼ 0.003), and percent volume obstruction (19.6 vs. 13.0%,
P ¼ 0.001). Less protruding stent struts were found in lesions
with (0.06%) vs. without NA (0.40%, P ¼ 0.023).
Quantitative coronary angiography
analysis
A total of 704 untreated, native coronary artery segments at base-
line were matched with the corresponding segments at 5 years
follow-up, allowing the assessment of longitudinal changes over
time (Table 3). A reduction in MLD was observed in both groups
(with and without NA). The reduction in MLD of untreated, native
coronary artery segments between baseline and 5-year follow-up
was more pronounced in lesions of patients with NA (20.25 mm,
95% CI 20.36 to 20.17) compared with lesions of patients without
NA (20.13 mm, 95% CI 20.17 to 20.10, P ¼ 0.002) (Figure 4).
Similarly, the change of % diameter stenosis was higher in lesions
of patients with NA (6.0%, 95% CI 5.3–11.1) compared with those
without NA (4.3%, 95% CI 2.5–6.2, P ¼ 0.048). Two representative
examples of patients with NA lesion formation and native athero-
sclerosis progression are provided in Figure 5. We performed four
sensitivity analyses: In the first, we applied a more strict definition
of NA lesions requiring a longitudinal extension of 1.5 mm. With
this criteria, the difference in mean change in MLD remained un-
changed (20.32 vs. 20.13 mm, P ¼ 0.0005) (Supplementary ma-
terial online, Table S3). In the second sensitivity analysis, we only
included patients treated with PES and found similar MLD changes
(20.27 vs. 20.11 mm, P ¼ 0.004) (Supplementary material online,
Figure 2 Serial quantitative coronary angiography analysis. This figure shows the serial quantitative coronary angiography analysis within
matched regions of all untreated coronary artery segments at baseline (A and B) and at 5-year follow-up (C and D). Untreated coronary artery
segments were classified according to the modified AHA/ACC classification. The treated lesion is shown in the proximal left anterior descending
(LAD).
M. Taniwaki et al.2170
Table S4). Third, we applied sensitivity analysis assessing the change
in MLD in non-target vessels vs. non-stented target vessels and
found consistent results[non-target vessels (20.26 vs. 20.13 mm,
P ¼ 0.003), non-stented segments in target vessel (20.30 vs.
20.09 mm, P ¼ 0.02)] (Supplementary material online, Table S5).
Fourth, we compared the change in MLD between ACS and
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Table 1 Neoatherosclerosis-related findings of lesions undergoing optical coherence tomography analysis
Overall (N 5 88) SES (N 5 41) PES (N 5 47) P-value
Plaque type
NA (lesions with at least one plaque) 14 (15.9) 2 (4.9) 12 (25.5) 0.009
Fibrocalcific plaque 5 (5.7) 0 (0) 5 (10.6) 0.058
FA 10 (11.4) 2 (4.9) 8 (17.0) 0.10
Thick-cap FA 8 (9.1) 1 (2.4) 7 (14.9) 0.06
Thin-cap CFA 3 (4.3) 1 (2.4) 2 (4.3) 1.00
Incidence of multiple fibrocalcific plaques 1 (1.1) 0 (0) 1 (2.1) 1.00
Incidence of multiple thick-cap FA 1 (1.1) 0 (0) 1 (2.1) 1.00
Incidence of multiple thin-cap FA 0 (0) 0 (0) 0 (0)
Multiple neoatherosclerotic plaque 4 (4.5) 0 (0) 4 (8.5) 0.12
Non-plaque-related neoatherosclerotic findings
Signal rich band 28 (31.8) 6 (14.6) 22 (46.8) 0.001
Microvessel 2 (2.3) 0 (0) 2 (4.3) 0.50
Intimal tear 1 (1.1) 0 (0) 1 (2.1) 1.00
Intra-luminal thrombus 10 (11.4) 4 (9.8) 6 (12.8) 0.75
Erosion 3 (3.4) 3 (7.3) 0 (0) 0.10
Plaque rupture 0 (0) 0 (0) 0 (0)
Other findings
Peri-strut low-signal intensity layer 15 (17.1) 2 (4.9) 13 (27.7) 0.005
Lesions with any potential NA findings 36 (40.9) 10 (24.4) 26 (55.3) 0.005
Values are the number of patients (%), one stented lesion per patient underwent OCT analysis. P-values from Fisher’s exact test. Plaque defined as at least eight consecutive
frames (≥1 mm) with fibrocalcific, thick- or thin-cap fibroatheroma. Non-plaque findings defined as at least three consecutive frames with the same finding.
Figure 3 Longitudinal neoatherosclerosis lesion map. The stented vessel regions are represented by black lines with indication of the location of
neoatherosclerosis plaque types (colored) and non-analysable frames (grey). The longitudinal resolution is 0.125 mm. Stents with neoathero-
sclerosis plaques (i.e. ≥1 mm longitudinal extension) are shown in the upper part of the figure and stents without in the lower part.
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stable patients, again with similar results [ACS (20.27 vs.
20.11 mm, P ¼ 0.021), stable CAD (20.25 vs. 20.14, P ¼
0.044)]) (Supplementary material online, Table S6).
No significant difference in terms of the angiographic SYNTAX
score at index procedure was observed (NA: 13.3 vs. no-NA:
11.0, P ¼ 0.78).
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Table 2 Baseline clinical, procedural, stented lesion, and angiographic characteristics
Patients with NA (N5 14) Patients without NA (N5 74) P-value
Age (years) 56 (49.0–71.5) 60 (53.0–64.0) 0.89
Male 10 (71.4) 60 (81.1) 0.47
BMI (kg/m2) 27.4 (24.9–28.9) 27.8 (24.7–30.8) 0.75
Cardiac risk factors
Diabetes mellitus 3 (23.1) 13 (18.8) 0.71
Hyperlipidaemia 8 (61.5) 42 (60.9) 0.47
Hypertension 10 (76.9) 41 (59.4) 0.35
Current smoker 6 (46.2) 29 (42.0) 1.00
Previous PCI 4 (28.6) 15 (20.3) 0.49
Previous MI 3 (21.4) 22 (29.7) 0.75
Left ventricular ejection fraction (%) 62.5 (52.5–65.0) 60 (50.0–65.0) 0.97
Clinical presentation
Stable CAD 6 (42.9) 30 (40.5) 1.00
Acute coronary syndrome 8 (57.1) 44 (59.5) 1.00
Unstable angina 0 5 (6.7) 1.00
NSTEMI 6 (42.9) 14 (18.9) 0.08
STEMI 2 (14.3) 25 (33.8) 0.21
TL coronary artery
LAD 7 (50.0) 35 (47.3) 1.00
LCX 3 (21.4) 17 (23.0) 1.00
LMCA 0 (0.0) 2 (2.7) 1.00
RCA 4 (28.6) 20 (27.0) 1.00
Pre-procedure angiographic measurements
MLD (mm) 0.35 (0.09–0.54) 0.41 (0.16–0.76) 0.61
RVD (mm) 2.91 (2.48–3.00) 2.86 (2.54–3.14) 0.78
Diameter stenosis (%) 86.5 (82.0–96.8) 86.0 (75.0–95.0) 0.59
SYNTAX score 13.3 (6.5–15.5) 11 (7.0–17.0) 0.78
Procedures
Lesion length (mm) 14.5 (10.0–20.0) 15.0 (10.0–20.0) 0.98
Total stent length (mm) 19.0 (13.0–20.8) 18.0 (13.0–23.0) 0.95
SES implantation 2 (14.3) 39 (52.7) 0.009
PES implantation 12 (85.7) 35 (47.3) 0.009
Post-procedure angiographic measurements
MLD in segment (mm) 2.73 (2.62–3.20) 2.63 (2.28–3.00) 0.77
MLD in stent (mm) 2.68 (2.48–2.93) 2.64 (2.38–3.00) 0.88
RVD in segment (mm) 2.83 (2.77–3.17) 2.94 (2.50–3.24) 0.93
RVD in stent (mm) 2.94 (2.53–3.04) 2.85 (2.54–3.06) 0.99
Diameter stenosis (%)
In-segment 4.0 (4.0–6.0) 7.0 (4.0–12.0) 0.38
In-stent 6.0 (1.8–7.0) 7.0 (3.0–9.0) 0.28
Values shown are median (lower to upper quartile) or number (%). P-values from Wilcoxon rank-sum test or Fisher’s exact test.
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Clinical events
Clinical events throughout 5 years are summarized in Table 4.
Non-TL revascularizations occurred more frequently in patient
with NA (78.6%) when compared with patients without NA
[44.6%, odds ratio ¼ 4.56 (95% CI 1.17–17.69), P ¼ 0.028]. Similar-
ly, non-TVR (71.4 vs. 43.2%, OR ¼ 3.28 (0.94–11.42), P ¼ 0.06)
was more frequently observed in the NA lesion group. We further
assessed clinical events over additional 4 years after OCT and did
not record any differences between patients with vs. without NA
(Supplementary material online, Table S7).
Discussion
This cohort study of patients with coronary artery disease
previously treated with DES allowed to correlate the process
of in-stent NA with native atherosclerosis progression, due to
its design including serial angiographic surveillance, annual
clinical follow-up, and intra-coronary imaging using OCT at 5 years.
Association between neoatherosclerosis
and native coronary atherosclerosis
progression
The principal finding of this cohort study is a significant association
between in-stent NA and the progression of native coronary ath-
erosclerosis. The more pronounced reduction in MLD of NA com-
pared with non-NA patients was of similar extent in the target and
non-target vessel and in ACS vs. stable CAD patients, attesting to
the robustness of the results. The P-value of 0.002 obtained from
a robust rank-based method for the comparison of MLD change be-
tween patients with and without NA indicates strong evidence
against the null hypothesis of no difference, even when considering
stringent criteria. In the presence of an initially conservative treat-
ment approach in non-target segments, the ability of MLDs to
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Table 3 Quantitative coronary angiography analysis of non-target lesion segments
Patients with NA median (95% CI) Patients without NA median (95% CI) P-value
Number of patients N ¼ 14 N ¼ 73a
Number of segment N ¼ 120 N ¼ 584
Number of segments per patient 8.6 8.0
Segment localizationb 0.31
LAD 38 (32%) 194 (33%) 0.82
LCX 34 (28%) 197 (34%) 0.30
RCA 48 (40%) 193 (33%) 0.18
RVD (mm)
BL 2.32 (2.23–2.67) 2.36 (2.28–2.47) 0.94
FUP 2.38 (2.12–2.5) 2.38 (2.28–2.44) 0.50
Mean segment length per pat. (mm)
BL 30.76 (29.53–33.21) 30.94 (29.57–31.98) 0.68
FUP 31.37 (29.5–32.66) 31.34 (29.48–32.5) 0.99
Total segment length per pat. (mm)
BL 278 (249–302) 256 (237–274) 0.15
FUP 280 (251–293) 255 (236–281) 0.34
Minimal Lumen diameter (mm)
BL 1.9 (1.66–2.16) 1.9 (1.84–2.01) 0.62
FUP 1.54 (1.41–1.88) 1.78 (1.72–1.88) 0.072
Changec in MLD (FUP-BL) 20.25 (20.36 to 20.17) 20.13 (20.17 to 20.10) 0.002
Diameter stenosis (%)
BL 20.94 (19.15–22.55) 20.03 (18.45–21.92) 0.32
FUP 27.67 (25.21–35.9) 23.61 (21.49–28.79) 0.063
Changec in %DS (FUP-BL) 6.03 (5.28–11.06) 4.31 (2.47–6.24) 0.048
Values are medians over several patients (95% CIs from non-parametric bootstrap). P-values from Wilcoxon rank-sum test. Patient-level outcomes derived as the mean from
several segments.
QCA, quantitative coronary angiogram; FUP, follow-up; BL, baseline.
aIn one patient allocated in the non-NA group, the baseline angiography was not available and thus, this patient had to be excluded from the serial QCA analysis.
bReported as count (%), P-values from Pearson x2-test.
cChange was derived at the level of segments.
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change over time appears limited. The observed delta of 0.12 mm
correspond to 0.8 pooled SD units, indicating a large biological sig-
nal. Of note, the change in MLD did result in significant differences in
non-TL revascularizations.
The mechanism underlying in-stent NA are poorly understood
and it is believed to be a multifactorial process. It has been suggested
that NA occurs in the context of incompetently regenerated endo-
thelium, which results in an excessive uptake of circulating lipids and
leucodiapedesis leading to an accelerated atherosclerosis formation
within the neointima.11 Of note, in a recent ex vivo histological ana-
lysis NA was observed at a similar frequency following implantation
of new generation everolimus-eluting stents compared with early
generation DES despite evidence of other signs of improved arterial
healing.12 These findings suggest that small alterations of the endo-
thelium within the neointima may be sufficient to determine an
accelerated in-stent NA formation. As NA is less frequent and
occurs later in BMS compared with DES, the anti-proliferative agent
released from DES may be suspected as a causative factor. Our
findings indicate that NA is more likely to develop in patients with
a progressive native atherosclerosis phenotype during long-term
follow-up. Therefore, pathogenetic factors contributing to the
progression of native atherosclerosis appear to be similar to those
involved in NA formation. Of note, coronary artery disease com-
plexity as assessed by the angiographic SYNTAX score at baseline
was comparable in patients with and without evidence of in-stent
NA, suggesting that the observed association between NA and na-
tive atherosclerosis progression is independent from the initial dis-
ease severity. It could be assumed that patients with unfavourable
plaque phenotypes show a more aggressive NA formation and
that the atherosclerotic progression at non-target sites detected
throughout 5 years are related to the more aggressive disease al-
ready present at baseline. In this context, the lack of a baseline
OCT is a limitation; however, we did not observe any association
between NA formation and clinical indication (ACS vs. stable).
It could be hypothesized that therapeutic strategies known to
attenuate atherosclerosis progression—such as high-dose statin
therapy—may be also effective to suppress the development or
progression of NA. We investigated whether patients with in-stent
NA were less adherent to evidence based cardiovascular medica-
tions including statins, but did not observe any differences between
groups. Similarly, the reduction in LDL-C and the increase in
HDL-C, both known to be associated with atherosclerosis progres-
sion, were not different between patients with comparedwith those
without NA lesions. Based on the relatively small sample size and
of this cohort, we consider these observations the latter results
as indefinite.
Frequency of neoatherosclerosis
The reported frequency of in-stent NA substantially differs from
previous studies. This is explained at least in part by the variety of
NA definitions applied and the substantial differences in patient se-
lection. In a human pathology study, Nakazawa and colleagues re-
ported a frequency of 31% in 209 DES lesions at a mean of 1.2
years after stent implantation by defining NA as the presence of ei-
ther peri-strut foamy macrophage clusters, fibroatheromas, thin-
cap fibroatheromas, or plaque ruptures with thrombosis.4 More re-
cently, the same group of investigators observed a similar frequency
of NA among patients treated with everolimus-eluting stents (29%),
SES (35%), and PES (19%) 30 days to 3 years after stent implant-
ation.12 The overall frequency of any NA-related findings in our
OCT investigation (40.9%) was comparable with these two path-
ology studies with the exception that NA was more frequently ob-
served after PES implantation—which could be explained by a
substantially different patient selection and a longer follow-up
time. In vivo studies using OCT to describe the frequency of in-stent
NA are scarce. Yonetsu and colleagues defined NA as the presence
of lipid-laden neointima and reported a frequency of 75% at 4 years of
follow-up.13 We found a lower frequency, even when considering a
wider definition under the inclusion of any potential in-stent
NA-related findings. A possible explanation for this discrepancy is
the higher proportion of symptomatic patients in the study by Yonet-
su and colleagues. Another explanation is the risk of overestimation
of NA using OCT, as suggested by Nakano and colleagues. In this
study, a conservative definition of NA was applied requiring a longi-
tudinal extension of at least 1.0 mm in length under the exclusion of
potential macrophage accumulation and fibrin deposition by identify-
ing signal rich bands and peri-strut low-signal intensity areas.14
Predictors of neoatherosclerosis lesion
formation
With the exception of device type, we have not observed any differ-
ences in baseline clinical, procedural, or angiographic variables be-
tween patients with NA when compared with those without NA
at 5 years. In a histology study, younger age, longer implant duration,
and SES and PES usage were identified as independent predictors
Figure 4 Quantitative angiographic analysis. Box-plot represen-
tation of the per-patient mean angiographic change in minimal lu-
men diameter (minimal lumen diameter follow-up 2 minimal
lumen diameter baseline) from untreated coronary artery seg-
ments that were serially assessed andmatched. Analysis is stratified
according to presence (N ¼ 14 patients) or absence (N ¼ 74 pa-
tients) of neoatherosclerosis plaques in the stented vessel that
underwent optical coherence tomography analysis. Lower and
upper box edges are the quartiles and thick line is the median. A
horizontal reference line at change ¼ 0 is drawn.
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Figure 5 (5A) Association between neoatherosclerosis lesion formation and atherosclerosis progression in untreated coronary artery seg-
ments. This figure shows a representative example of a patient with a TCFA within the neointima (F and G) displaying a strong attenuation, which
prevents the visualization of the stent struts behind the lipid pool/necrotic core. Arrowheads indicate the localization of the minimal cap thickness.
In the distal part of the right coronary artery (RCA), a non-significant stenosis at baseline (C) progressed over 5 years to a significant stenosis (D).
The longitudinal view is presented in (E). (5B) Association between neoatherosclerosis lesion formation (fibrocalcific plaque) and atherosclerosis
progression in untreated coronary artery segments. This figure shows a representative example of a patient with a fibrocalcific plaque within the
neointima (F and G) displaying a signal-poor region with low attenuation and sharp borders (asterisk). In the distal LAD and proximal RCA, a non-
significant stenosis at baseline (A and C) progressed over 5 years to a significant stenosis (B and D). The longitudinal view is presented in (E).
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of NA formation.4 Moreover, in an in vivo OCT study Yonetsu and
colleagues identified time from stent implantation, active smoking,
chronic kidney disease, and use of ACE-AR-II as independent pre-
dictors of NA.15 Our study results may assist in understanding
why active smoking and chronic kidney disease emerged as predic-
tors for NA formation, both established risk factors for native
atherosclerosis.
Clinical impact of neoatherosclerosis
The impact of NA on clinical outcomes has not been prospectively
investigated at this point in time. Observational studies and case
reports, however, suggest an association between NA lesions and
late stent failures.1,3We observed no significant differences in target
lesion related outcomes between patients with and without NA
during additional 4 years of follow-up. However, in view of the
selection of TLR-free patients throughout 5 years and the relatively
small number of patients with NA in our study, further prospective
investigations are required for definitive conclusions on the clinical
impact of NA.
Study limitations
Our study needs to be interpreted in light of some limitations. First,
only selected patients free from TL-related events were considered
eligible for angiographic and OCT long-term evaluation. Thus, the
generalizability of our findings may be limited. Second, the sample
size was relatively small. This limits secondary analyses focusing on
predictors of NA as well as the evaluation of the clinical impact
of NA. However, the findings related to our primary hypothesis
are statistically robust and mechanistically plausible. Third, we inves-
tigated the occurrence of NA in early generation DES that are
no longer used in clinical practice. It remains to be shown if our find-
ings apply to new generation DES, although new generation
everolimus-eluting stents have been reported to have a similar pro-
pensity to develop NA as early generation DES in a recent ex vivo
histological analysis. Although OCT has been validated against
histology for the assessment of atherosclerotic plaque composition
and phenotype, we are unaware of a dedicated validation study for
the diagnosis of in-stent NA. Whilst the assessment of calcifications
is not expected to be the cause of misinterpretations, the differen-
tiation between in-stent fibroatheroma and macrophage accumula-
tions, artefacts (e.g. tangential drop out), fibrin accumulations
surrounding stent struts, hypersensitivity reaction (T-lymphozyte
and eosinophil infiltration), granulation tissue or the penetration
of necrotic core from the original plaque appears more challenging
and might be the source of misdiagnosis and a reason for NA over-
reporting.16 Serial QCA was performed one single projection,
which may results in an underestimation of angiographic lesion pro-
gression. The use of similar projections for serial QCA analyses,
however, prevented an overestimation of the observed angio-
graphic lesion progression.
Conclusions
The formation of in-stent NA is closely associated with progression
of native coronary atherosclerosis, suggesting similarities in the
pathophysiologic mechanisms of these two entities. These findings
may have important clinical implications for the development and
implementation of strategies to prevent NA among patients under-
going PCI.
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Table 4 Clinical events up to 5 years angiographic follow-up
Patients with NA (N 5 14) Patients without NA (N5 74) Odds ratio (95% CI) P-value
Non-TVR 10 (71.4%) 32 (43.2%) 3.28 (0.94–11.42) 0.062
Non-TLRa 11 (78.6%) 33 (44.6%) 4.56 (1.17–17.69) 0.028
Non-TLR TVR 1 (7.1%) 5 (6.8%) – 1.000
Any revascularizationb 11 (78.6%) 37 (50.0%) 3.67 (0.95–14.22) 0.060
Any MI 0 (0%) 2 (2.70%) – 1.000
No. of events (%) are reported. Median follow-up time was 1933 days (IQR: 1847–2012). Odds ratios and P-values from logistic regression model. For each patient, clinical events
were included until and including the day of 5 years imaging follow-up. If ,5 events, P-values from Fisher’s exact test.
aNon-TVR or TVR excluding TLR.
bNon-TVR or TVR including TLR.
M. Taniwaki et al.2176
References
1. Kang SJ, Mintz GS, Akasaka T, Park DW, Lee JY, Kim WJ, Lee SW, Kim YH, Whan
Lee C, Park SW, Park SJ. Optical coherence tomographic analysis of in-stent
neoatherosclerosis after drug-eluting stent implantation. Circulation 2011;123:
2954–2963.
2. Taniwaki M, Windecker S, Ra¨ber L. Neoatherosclerosis as reason for stent failures
beyond 5 years after drug-eluting stent implantation. Eur Heart J 2014;35:1980.
3. Takano M, Yamamoto M, Inami S, Murakami D, Ohba T, Seino Y, Mizuno K. Ap-
pearance of lipid-laden intima and neovascularization after implantation of bare-
metal stents extended late-phase observation by intracoronary optical coherence
tomography. J Am Coll Cardiol 2009;55:26–32.
4. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD,
Finn AV, Virmani R. The pathology of neoatherosclerosis in human coronary im-
plants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57:1314–1322.
5. Ra¨ber L, Baumgartner S, Garcia-Garcia HM, Kalesan B, Justiz J, Pilgrim T,
Moschovitis A, Khattab AA, Buellesfeld L, Wenaweser P, Meier B, Serruys PW,
Juni P, Windecker S. Long-term vascular healing in response to sirolimus- and
paclitaxel-eluting stents: an optical coherence tomography study. JACC Cardiovasc
Interv 2012;5:946–957.
6. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, Togni M,
Billinger M, Tuller D, Seiler C, Roffi M, Corti R, Sutsch G, Maier W, Luscher T,
Hess OM, Egger M, Meier B. Sirolimus-eluting and paclitaxel-eluting stents for
coronary revascularization. N Engl J Med 2005;353:653–662.
7. Ra¨ber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, Cook S,
Moschovitis A, Vogel R, Kalesan B, Seiler C, Eberli F, Luscher TF, Meier B, Juni P,
Windecker S. Five-year clinical and angiographic outcomes of a randomized
comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the
Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization
LATE trial. Circulation 2011;123:2819–2828.
8. Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, Bouma B,
Bruining N, Cho JM, Chowdhary S, Costa MA, de Silva R, Guagliumi G,
Holm NR, Kubo T, Kume T, Kyono H, Lam CC, Lamouche G, Lee DP, Leon MB,
Maehara A, Manfrini O, Mintz GS, Mizuno K, Nadkarni S, Okura H, Otake H,
Pietrasik A, Prati F, Ra¨ber L, Radu MD, Rieber J, Riga M, Rollins A, Rosenberg M,
Sirbu V, Serruys PW, Shimada K, Shinke T, Shite J, Siegel E, Sonoda S, Suter M,
Takarada S, Tanaka A, Terashima M, Thim T, Uemura S, Ughi GJ, van
Beusekom HM, van der Steen AF, van Es GA, van Soest G, Virmani R,
Waxman S,Weissman NJ,Weisz G. Consensus standards for acquisition, measure-
ment, and reporting of intravascular optical coherence tomography studies. J Am
Coll Cardiol 2012;59:1058–1072.
9. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, Murphy ML,
Roe BB. A reporting system on patients evaluated for coronary artery disease. Cir-
culation 1975;51:5–40.
10. Serruys PW, Unger F, van Hout BA, van den Brand MJ, van Herwerden LA, van
Es GA, Bonnier JJ, Simon R, Cremer J, Colombo A, Santoli C, Vandormael M,
Marshall PR, Madonna O, Firth BG, Breeman A, Morel MA, Hugenholtz PG. The
ARTS study. Semin Interv Cardiol 1999;4:209–219.
11. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS,
Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell re-
covery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol
2008;52:333–342.
12. Otsuka F, Vorpahl M, Nakano M, Foerst J, Newell JB, Sakakura K, Kutys R, Ladich E,
Finn AV, Kolodgie FD, Virmani R. Pathology of second-generation everolimus-
eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in hu-
mans. Circulation 2014;129:211–223.
13. Yonetsu T, Kim J-SS, Kato K, Kim S-JJ, Xing L, Yeh RW, Sakhuja R, McNulty I, Lee H,
Zhang S, Uemura S, Yu B, Kakuta T, Jang I-KK. Comparison of incidence and time
course of neoatherosclerosis between bare metal stents and drug-eluting stents
using optical coherence tomography. Am J Cardiol 2012;110:933–939.
14. Nakano M, Vorpahl M, Otsuka F, Taniwaki M, Yazdani SK, Finn AV, Ladich ER,
Kolodgie FD, Virmani R. Ex vivo assessment of vascular response to coronary
stents by optical frequency domain imaging. JACC Cardiovasc Imaging 2012;5:
71–82.
15. Yonetsu T, Kato K, Kim SJ, Xing L, Jia H, McNulty I, Lee H, Zhang S, Uemura S,
Jang Y, Kang SJ, Park SJ, Lee S, Yu B, Kakuta T, Jang IK. Predictors for neoathero-
sclerosis: a retrospective observational study from the optical coherence tomog-
raphy registry. Circ Cardiovasc Imaging 2012;5:660–666.
16. Nakano M, Otsuka F, Virmani R. Letter by Nakano et al regarding article “Optical
coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting
stent implantation”. Circulation 2011;124:954.
Neoatherosclerosis and native coronary artery disease progression 2176a
